# Risk Factors for External Ventricular Drainage–Related Infection

A Systematic Review and Meta-analysis

Jialei Zhou, MM, Yi Zhong, MM, Xiang Li, MD, Hang Li, MM, Jiahe Wang, MM, Siyuan Yang, MM, and Gang Chen, MD, PhD

Neurology: Clinical Practice 2023;13:e200156. doi:10.1212/CPJ.0000000000200156

Correspondence Dr. Chen nju\_neurosurgery@163.com

# Abstract

# **Background and Objectives**

External ventricular drainage (EVD) is one of the most commonly performed neurosurgical procedures, but EVD-related infection constitutes a significant health concern. Yet, little consensus identifies the risk factors for the development of EVD-related infection. Therefore, we performed a meta-analysis to systematically summarize existing evidence on the incidence and risk factors for EVD-related infection.

## **Methods**

PubMed, Embase, and the Cochrane Library databases from database inception to February 28, 2022, were searched for all studies investigating the incidence and risk factors for EVD-related infection. Data were assessed by R-4.2.0 software. The meta-analysis was used to calculate pooled odds ratios (OR) and 95% confidence intervals (CI).

#### Results

A total of 48 studies were included. Among the 29 factors analyzed, statistically significant risk factors were subarachnoid hemorrhage(SAH)/intraventricular hemorrhage(IVH) (OR = 1.48, 95% CI = 1.20–1.82, p < 0.001), concomitant systemic infection (OR = 1.90, 95% CI = 1.34–2.70, p < 0.001), other neurosurgical procedures (OR = 1.76, 95% CI = 1.02–3.04, p = 0.041), change of catheter (OR = 5.05, 95% CI = 3.67–6.96, p < 0.001), bilateral EVDs (OR = 2.25, 95% CI = 1.03–4.89, p = 0.041), (cerebrospinal fluid) CSF leak (OR = 3.19, 95% CI = 2.12–4.81, p < 0.001) and duration of EVD >7 days (OR = 4.62, 95% CI = 2.26–9.43, p < 0.001). The use of silvercoated catheters (OR = 0.57, 95% CI = 0.38–0.87, p = 0.008) and antibiotic-impregnated catheters (OR = 0.60, 95% CI = 0.41–0.88, p = 0.009) might help reduce the risk of infection. No significant difference was indicated in studies evaluating factors like diabetes mellitus (OR = 1.25, 95% CI = 0.90–1.75, p = 0.178), steroids used (OR = 1.52, 95% CI = 0.96–2.4, p = 0.074), prophylactic antibiotics(OR = 0.87, 95% CI = 0.66–1.14, p = 0.308).

## Discussion

The meta-analysis of various relevant factors in the onset of EVD-related infection in patients submitted to EVD enabled us to establish a more probable profile of the patients who are more likely to develop it during the treatment.

External ventricular drainage (EVD) is one of the most commonly performed neurosurgical procedures for monitoring intracranial pressure and temporarily diverting CSF.<sup>1</sup> EVD placement can be a lifesaving procedure in patients with neurologic decline caused by subarachnoid hemorrhage (SAH), intraventricular hemorrhage (IVH), intraparenchymal hemorrhage (IPH),

Department of Neurosurgery & Brain and Nerve Research Laboratory, The First Affiliated Hospital of Soochow University Suzhou, Jiangsu Province, China.

Funding information and disclosures are provided at the end of the article. Full disclosure form information provided by the authors is available with the full text of this article at Neurology.org/cp.

Copyright © 2023 American Academy of Neurology

Copyright © 2023 American Academy of Neurology. Unauthorized reproduction of this article is prohibited.

traumatic brain injury (TBI), intracranial infection, brain tumor, or shunt failure.<sup>2-4</sup> As the "gold standard" among the array of methods used to monitor intracranial pressure, the number of EVD placements has increased.<sup>5-7</sup> However, there are concerns regarding the high rate of complications such as malposition, hemorrhage, and, the most common, EVD-related infections.<sup>5,8-12</sup> The incidence of EVD-related infections, including meningitis and ventriculitis, varies from <5% to 20% depending on the criteria of diagnosis.<sup>13</sup> EVD-related infections lead to prolonged hospital stay, increased costs, and higher mortality.<sup>14</sup> Thus, it is essential to identify the risk and associated factors of these infections to develop preventive interventions.

EVD-related infections may arise from catheter colonization by inoculation of skin flora during insertion or manipulation of the drainage system during the postoperative period.<sup>15</sup> Therefore, risk factors believed to be associated with EVD-related infection include previous craniotomy, systemic infection, duration of EVD, catheter irrigation, site leaks, and frequency of CSF sampling.<sup>16</sup> However, most of these factors have not been carefully adjusted. To inform the creation of evidence-based care bundles, we performed a meta-analysis to identify the real risk factors.

# Methods

This meta-analysis was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. As our study was based on published data, ethical approval or patient consent was not required. In addition, only studies that reported ethical approval or patient consent were included in the meta-analysis.

# Search Strategy

Two investigators performed a systematic study search using keywords "External ventricular drainage," "External ventricular drain," "EVD," "infection," "infestation," and all related free search terms in PubMed, Embase, and the Cochrane Library databases from database inception to February 28, 2022. To avoid omissions, we manually searched the reference lists of all the relevant articles.

# **Inclusion and Exclusion Criteria**

The inclusion criteria were as follows: (1) study type: observational and interventional studies; (2) population: patients older than 18 years; (3) articles had to have a case-control, longitudinal, or case-crossover design; (4) studies mentioning a specific definition of EVD-related infection; and (5) studies reporting crude or adjusted effect estimates with corresponding 95% confidence intervals (CIs) or results that allowed the calculation of risk ratios (RRs) or odds ratios (ORs).

The exclusion criteria were as follows: (1) unavailability of sufficient data that are studied in this meta-analysis; (2) unclear definition of EVD-related infection; (3) reviews, letters, meeting abstracts, supplements, and case reports; and (3) studies not differentiating EVD from lumbar drainage (LD).

## **Data Extraction**

Two investigators extracted the following data from the included studies: first author, year, country, sample size, study design, patient demographics, and the presence of risk factors. They recorded the data using a dedicated data extraction form.

# **Quality Assessment**

We evaluated the quality of cohort studies according to the Newcastle-Ottawa Scale (NOS), which is a commonly used tool to assess the quality of observational studies in metaanalyses.<sup>17</sup> We assessed each study using 8 items categorized into 3 domains: selection of the study groups, comparability of the groups, and ascertainment of either exposure or outcome of interest for cohort studies. Stars (ranging from zero to 9 stars) were assigned to items of good quality.

# **Statistical Analysis**

Data were assessed using R-4.2.0. We obtained ORs with 95% CIs for various risk factors for EVD-related infections. ORs greater than 1 indicate an increased risk of infection, whereas ORs less than 1 indicate a decreased risk. We assessed statistical significance using 95% confidence intervals (CIs). If the 95% CI did not include a neutral value of 1, we considered the risk to be statistically significant. Heterogeneity was classified as moderate ( $I^2 = 25\%-50\%$ ), substantial ( $I^2 =$ 50%–75%), or considerable ( $I^2 \ge 75\%$ ).<sup>18</sup> A random-effect or fixed-effect model was used according to the degree of heterogeneity found.<sup>19</sup> To determine the source of heterogeneity and assess the influence of each study on the final results, we excluded 1 study in sequence through a sensitivity analysis. Considering the extensive placement of antibioticimpregnated catheters, a subgroup analysis was performed to investigate the stability of the consolidated results. Based on the study design, the subgroups were classified as observational studies and randomized control trials (RCTs).


# Results


## **Study Selection**

A total of 1268 articles were identified from PubMed, Embase, and Cochrane Library databases. A total of 1192 records were removed because of duplication (465 records) or irrelevance to the study (726 records). Twenty-nine other records were excluded because they were comments (2 records), reviews (6 records), meta-analyses (3 records), conference abstracts (9 records), studies not differentiating EVD and LD (3 records), and studies including minor patients (6 records). Forty-eight studies were included in this meta-analysis. The entire process of study search, selection, and inclusion is presented in Figure 1.

# **Study Characteristics**

The details of the included studies are presented in eTable 1 (links.lww.com/CPJ/A438). The 48 included studies were published between 1986 and 2022.<sup>7,16,20-60,e1-e5</sup> The median





EVD-related infection rate was 10.7% (IQR 7.3%–20.9%), and the median number of patients included was 207 (IQR 119.25–335). Most studies included defined EVD-related infections by considering pathologic CSF findings, microbiology, and clinical signs based on US Centers for Disease Control and Infection/National Healthcare Safety Network (CDC/NHSN) surveillance definitions.<sup>e6</sup>

#### **Quality Assessment**

Forty-four studies were evaluated according to the NOS. Thirty-eight studies were assessed as having 3 or more stars for the appraisal of the selection domain in the NOS checklist. Most of the included studies had 1 of 2 stars in the comparability domain. For the outcome domain, 36 studies were appraised as having 3 stars (eTable 2, links.lww.com/CPJ/A438).

#### **Risk and Associated Factors**

In total, we analyzed 29 different factors and divided them into 3 categories based on timing, including 17 preoperative factors, 7 intraoperative factors, and 5 postoperative factors. A summary of the results of the meta-analysis is presented in Table.

Preoperative risk factors for EVD-related infection found in our meta-analysis included SAH/IVH (OR = 1.48, 95% CI 1.20–1.82,

p < 0.001), concomitant systemic infection (OR = 1.90, 95% CI 1.34–2.70, p < 0.001), and other neurosurgical procedures (OR = 1.76, 95% CI 1.02–3.04, p = 0.041). However, factors including male (OR = 0.98, 95% CI 0.89–1.08, p = 0.664), ICH (OR = 0.86, 95% CI 0.66–1.12, *p* = 0.249), brain tumor (OR = 1.11, 95% CI 0.84-1.47, p = 0.459), brain trauma (OR = 0.83, 95%) CI 0.61–1.13, p = 0.240), hydrocephalus (OR = 1.34, 95% CI 0.69–2.60, *p* = 0.388), cerebrovascular accidents (OR = 1.57, 95%) CI 0.75–3.28, p = 0.226), ischemic stroke (OR = 1.03, 95% CI 0.45-2.33, p = 0.947), diabetes mellitus (OR = 1.25, 95%) CI 0.90–1.75, p = 0.178), steroids used (OR = 1.52, 95% CI 0.96–2.4, p = 0.074), nonintracranial tumors (OR = 0.93, 95% CI 0.51-1.70, p = 0.821, hypertension (OR = 1.01, 95%) CI 0.78–1.32, *p* = 0.935), cardiovascular disease (OR = 0.77, 95%) CI 0.37–1.59, *p* = 0.473), Charlson score > 2 (OR = 1.39, 95% CI 0.84–2.30, *p* = 0.200), and Glasgow Coma Scale (GCS) < 9 (OR = 1.16, 95% CI 0.68–1.99, p = 0.587) were not significantly associated with infection (eFigures 1-3, links.lww.com/CPJ/A438).

Changes in catheter (OR = 5.05, 95% CI 3.67–6.96, p < 0.001), bilateral EVDs (OR = 2.25, 95% CI 1.03–4.89, p = 0.041), CSF leak (OR = 3.19, 95% CI 2.12–4.81, p < 0.001), and duration of EVD >7 days (OR = 4.62, 95% CI 2.26–9.43, p < 0.001) were risk factors during or after the procedures. In addition, the use

Copyright © 2023 American Academy of Neurology. Unauthorized reproduction of this article is prohibited.

Factors	Number of studies	OR (95% CI)	<i>p</i> Value	Methods (l <sup>2</sup> )
Preoperative risk factors: admission diagnosis				
SAH/IVH	21	1.48 (1.20–1.82)	<0.001	Fixed (28%)
ІСН	14	0.86 (0.66–1.12)	0.249	Fixed (0%)
Brain tumor	17	1.11 (0.84–1.47)	0.459	Fixed (0%)
Brain trauma	15	0.83 (0.61–1.13)	0.240	Fixed (39%)
Hydrocephalus	5	1.34 (0.69–2.60)	0.388	Fixed (23%)
Cerebrovascular accidents	3	1.57 (0.75–3.28)	0.226	Random (51%
lschemic stroke	2	1.03 (0.45–2.33)	0.947	Fixed (0%)
Preoperative risk factors: Others				
Male	30	0.98 (0.89–1.08)	0.664	Fixed (15%)
Concomitant systemic infection	6	1.90 (1.34–2.70)	<0.001	Fixed (0%)
Diabetes mellitus	11	1.25 (0.90–1.75)	0.178	Fixed (0%)
Steroids used	7	1.52 (0.96–2.41)	0.074	Fixed (0%)
Nonintracranial tumors	5	0.93 (0.51–1.70)	0.821	Fixed (0%)
Hypertension	5	1.01 (0.78–1.32)	0.935	Fixed (18%)
Cardiovascular disease	3	0.77 (0.37–1.59)	0.473	Fixed (22%)
Other neurosurgical procedures	7	1.76 (1.02,3.04)	0.041	Random (65%
Charlson score >2	2	1.39 (0.84–2.30)	0.200	Fixed (0%)
GCS <9	3	1.16 (0.68–1.99)	0.587	Fixed (0%)
ntraoperative risk factors				
Silver-coated catheters	4	0.57 (0.38–0.87)	0.008	Fixed (0%)
Antibiotic-impregnated catheters	7	0.60 (0.41–0.88)	0.009	Fixed (43%)
Change of catheter	10	5.05 (3.67–6.96)	0.000	Fixed (12%)
Bilateral EVDs	5	2.25 (1.03-4.89)	0.041	Random (54%
Insertion of catheters outside the OR	10	1.11 (0.60–2.07)	0.736	Random (85%
Insertion during craniotomy	3	2.02 (0.75–5.44)	0.166	Random (72%
Emergency operation	2	2.63 (0.47–14.59)	0.269	Random (61%
Postoperative risk factors				
CSF leak	8	3.19 (2.12-4.81)	<0.001	Fixed (37%)
Duration of EVD >7 d	3	4.62 (2.26-9.43)	<0.001	Fixed (0.0%)
Prophylactic antibiotics	14	0.87 (0.66–1.14)	0.309	Fixed (24%)
Artificial ventilation	2	1.58 (0.65–3.84)	0.308	Random (67%
Single room	2	1.95 (0.76–4.97)	0.163	Fixed (0%)

of silver-coated (OR = 0.57, 95% CI 0.38–0.87, p = 0.008) and antibiotic-impregnated (OR = 0.60, 95% CI 0.41-0.88, p = 0.009) catheters might help reduce the risk of infection (Figures 2 and 3).

We found no significant relationship between the following factors and EVD-related infection: insertion of catheters outside the OR (OR = 1.11, 95% CI 0.60–2.07, *p* = 0.736), insertion during craniotomy (OR = 2.02, 95% CI 0.75–5.44, *p* = 0.166),

Figure 2	Forest Plot Summarizin	g the Meta-anal	vsis of Studies Re	porting Intrao	perative Risk and	Associated Factors

	-				
Study	TE	seTE	Odds ratio	OR	95% CI
Factor = Silver-coa Ref. #24 Ref. #34 Ref. #32 Ref. #49 Fixed effect mode Random effects m Heterogeneity: /² =	-0.60 -0.37 -0.58 -0.70	0.3633 0.3861 0.7777 0.3895		0.55 0.69 0.56 0.50 <b>0.57</b> <b>0.57</b>	(0.27, 1.12) (0.33, 1.48) (0.12, 2.57) (0.23, 1.07) (0.38, 0.87) (0.38, 0.87)
Factor = Antibiotic e-Ref. #1 Ref. #25 Ref. #32 Ref. #40 Ref. #26 Ref. #33 Ref. #33 Ref. #23 Fixed effect mode Random effects m Heterogeneity: <i>P</i> <sup>2</sup> =	2.18 -0.54 -0.99 -1.01 -0.81 -0.25 -2.03	1.2499 0.5359 0.8784 0.7113 0.5379 0.2680 0.7692		<ul> <li>8.88</li> <li>0.59</li> <li>0.37</li> <li>0.36</li> <li>0.44</li> <li>0.78</li> <li>0.13</li> <li>0.60</li> <li>0.56</li> </ul>	(0.77, 102.90) (0.20, 1.67) (0.07, 2.08) (0.09, 1.47) (0.15, 1.28) (0.46, 1.32) (0.03, 0.60) (0.41, 0.88) (0.34, 0.90)
Factor = Change o Ref. #43 e-Ref. #1 Ref. #57 Ref. #48 Ref. #60 e-Ref. #2 e-Ref. #3 Ref. #42 Ref. #42 Ref. #45 Ref. #35 Fixed effect mode Random effects m Heterogeneity: I <sup>2</sup> =	2.77 1.08 1.53 -0.30 2.14 1.44 1.85 2.05 1.07 1.66	0.6300 0.5442 0.5110 1.0810 0.9086 0.3773 0.4968 0.4492 0.5531 0.3992		15.96 2.93 4.64 0.74 8.50 4.22 6.33 7.79 2.92 5.27 <b>5.05</b> <b>5.05</b>	(4.64, 54.86) (1.01, 8.52) (1.70, 12.63) (0.09, 6.15) (1.43, 50.45) (2.01, 8.84) (2.39, 16.77) (3.23, 18.78) (0.99, 8.62) (2.41, 11.53) (3.67, 6.96) (3.67, 6.96)
Factor = Bilateral I Ref. #43 Ref. #60 Ref. #53 e-Ref. #4 Ref. #52 Fixed effect mode Random effects m Heterogeneity: /² =	1.30 2.22 1.44 0.02 0.28 I model	0.9000 0.8531 0.6668 0.3984 0.3314 <i>p</i> = 0.07		3.67 9.23 4.21 1.02 1.32 <b>1.68</b> <b>2.25</b>	(0.63, 21.41) (1.73, 49.10) (1.14, 15.56) (0.47, 2.22) (0.69, 2.53) (1.09, 2.60) (1.03, 4.89)
Factor = Insertion e-Ref. #1 Ref. #41 Ref. #56 Ref. #54 e-Ref. #2 Ref. #40 Ref. #40 Ref. #40 Ref. #40 Ref. #27 e-Ref. #5 Ref. #60 Fixed effect mode Random effects <i>P</i>	1.79 1.30 0.47 -0.66 0.08 -0.17 0.36 0.40 -1.33 -0.33	0.6188 0.6541 1.1691 0.3986 0.3752 0.8919 0.7953 0.0756 0.2477 0.6795		6.00 3.66 1.60 0.52 1.08 0.84 1.43 1.49 0.27 0.72 <b>1.28</b> <b>1.11</b>	(1.79, 20.19) (1.01, 13.18) (0.16, 15.84) (0.24, 1.13) (0.52, 2.26) (0.15, 4.84) (0.30, 6.78) (1.29, 1.73) (0.16, 0.43) (0.19, 2.74) (1.12, 1.46) (0.60, 2.07)
Factor = Insertion e-Ref. #3 Ref. #59 e-Ref. #4 Fixed effect mode Random effects m Heterogeneity: /² =	1.81 0.48 0.03 I nodel	0.5619 0.4254 0.3572		6.12 1.62 1.03 <b>1.69</b> <b>2.02</b>	(2.03, 18.41) (0.70, 3.73) (0.51, 2.08) (1.04, 2.73) (0.75, 5.44)
Factor = Emergeno Ref. #39 Ref. #59 Fixed effect mode Random effects m Heterogeneity: /² =	0.09 1.84 I odel			1.09 6.27 <b>2.64</b> <b>2.63</b>	(0.24, 5.04) (1.38, 28.45) (0.90, 7.75) (0.47, 14.59)
		0.01	0.10 1.00 10.00 10	0.00	

Both fixed-effect and random-effect models were used. Notes: The light gray spots indicate the estimated odds ratio for each study, with the extending lines indicating the estimated 95% CI; the blue square indicates the weights of each study; and the light gray and maroon rhombuses indicate the estimated odds ratio (95% CI) calculated using the fixed-effect model and random-effect model, respectively, for all patients included. Insertion of catheters outside the OR = Insertion of catheters outside the operating room; TE = treatment estimate; seTE = standard error of treatment estimate.

Neurology.org/CP

#### Figure 3 Forest Plot Summarizing the Meta-analysis of Studies Reporting Postoperative Risk and Associated Factors

Study	TE	seTE	Odds ratio	OR	95% C
Factor = CSF leak			1		
Ref. #43	1.56	0.9280		4.76	(0.77, 29.34
Ref. #21	2.22	1.1416		9.19	(0.98, 86.06
Ref. #16	0.64	0.4692		1.90	(0.76, 4.76
e-Ref. #3	1.60	1.2450		4.95	(0.43, 56.85
Ref. #7	2.62	0.7122		13.70	(3.39, 55.33
Ref. #40	1.25	0.8626		3.50	(0.65, 18.98
Ref. #60	2.71	0.8958		15.10	(2.61, 87.39
Ref. #52	0.79	0.2997		2.20	(1.22, 3.96
Fixed effect model			•	3.19	(2.12, 4.8
Random effects model			-	4.27	(2.21, 8.24
Heterogeneity: I <sup>2</sup> = 37%,	t <sup>2</sup> = 0.3553	3, <i>p</i> = 0.13			
Factor = Duration of EVI	) > 7 days				
Ref. #38	2.75	1.1104		15.58	(1.77, 137.3
Ref. #35	1.40	0.4977		4.07	(1.54, 10.80
e-Ref. #4	1.35	0.6122		3.85	(1.16, 12.79
Fixed effect model			-	4.62	(2.26, 9.43
Random effects model			-	4.62	(2.26, 9.43
Heterogeneity: $I^2 = 0\%$ , $\tau^2$	= <0.0001	, <i>p</i> = 0.51			
Factor = Prophylactic an	tibiotics				
Ref. #22	-0.06	0.6249		0.95	(0.28, 3.22
Ref. #29	-1.04	0.4921		0.35	(0.13, 0.92
e-Ref. #1	-0.45	0.3780		0.64	(0.30, 1.33
Ref. #45	0.11	0.4676		1.11	(0.44, 2.78
Ref. #46	-1.58	0.6369		0.21	(0.06, 0.72
Ref. #16	0.54	0.3196		1.71	(0.92, 3.2
Ref. #56	0.16	0.7909		1.17	(0.25, 5.53
e-Ref. #2	-0.60	0.4823		0.55	(0.21, 1.42
Ref. #7	-0.20	0.6681		0.82	(0.22, 3.04
Ref. #59	-0.13	0.5157		0.88	(0.32, 2.4
Ref. #51	0.75	0.9545		2.11	(0.33, 13.72
Ref. #20	-0.69	1.0947		0.50	(0.06, 4.27
Ref. #47	0.26	0.4748		1.30	(0.51, 3.28
Ref. #53	0.20	0.7224		1.23	(0.30, 5.05
Fixed effect model			4	0.87	(0.66, 1.14
Random effects model Heterogeneity: <i>I</i> <sup>2</sup> = 24%, <sup>-</sup>	τ <sup>2</sup> = 0.1189	9, <i>p</i> = 0.19	*	0.83	(0.59, 1.18
Factor = Artificial ventila	ation				
Ref. #55	0.11	0.1784	<u>_</u>	1.12	(0.79, 1.59
e-Ref. #4	1.05	0.5062		2.85	(1.06, 7.69
Fixed effect model	1.05	0.0002		2.85 1.24	(0.89, 1.73
Random effects model				1.24	(0.65, 3.84
Heterogeneity: $I^2 = 67\%$ ,	τ <sup>2</sup> = 0.2952	2, <i>p</i> = 0.08			(0.00, 0.0-
Factor = Single room					
Ref. #39	0.67	0.8069		1.96	(0.40, 9.52
e-Ref. #4	0.66	0.5935		1.94	(0.61, 6.2
Fixed effect model				1.95	(0.76, 4.97
Random effects model				1.95	(0.76, 4.97

Both fixed-effect and random-effect models were used. Notes: The light gray spots indicate the estimated odds ratio for each study, with the extending lines indicating the estimated 95% CI; the blue square indicates the weights of each study; and the light gray and maroon rhombuses indicate the estimated odds ratio (95% CI) calculated using the fixed-effect model and random-effect model, respectively, for all patients included. EVD = external ventricular drainage; TE = treatment estimate; seTE = standard error of treatment estimate.

Figure 4 Forest Plot Summarizing the Subgroup Analysis of Studies Reporting the Effect of Antibiotic-Impregnated Catheters on Reduction of EVD-Related Infection Rate

Study	TE	seTE	Odds ratio	OR	95% CI	Weight (common) (%)	Weight (random) (%)
Study type = Obervational stud	y						
e-Ref. #1	2.18	1.2499		8.88	(0.77, 102.90)	2.4	3.7
Ref. #25	-0.54	0.5359		0.59	(0.20, 1.67)	13.2	16.1
Ref. #32	-0.99	0.8784		0.37	(0.07, 2.08)	4.9	7.0
Ref. #40	-1.01	0.7113		0.36	(0.09, 1.47)	7.5	10.2
Ref. #26	-0.81	0.5379		0.44	(0.15, 1.28)	13.1	16.0
Fixed effect model			-	0.55	(0.30, 0.99)	41.0	
Random effects model			-	0.55	(0.30, 0.99)		53.0
Heterogeneity: $I^2 = 29\%$ , $\tau^2 = <0.0$	)001, p =	0.23					
Study type = RCT							
Ref. #33	-0.25	0.2680		0.78	(0.46, 1.32)	52.6	38.1
Ref. #23	-2.03	0.7692		0.13	(0.03, 0.60)	6.4	8.9
Fixed effect model			-	0.64	(0.39, 1.05)	59.0	
Random effects model				0.37	(0.07, 2.06)		47.0
Heterogeneity: $l^2 = 79\%$ , $\tau^2 = 1.24$	144, p = (	0.03					
Fixed effect model			•	0.60	(0.41, 0.88)	100.0	
Random effects model		_		0.56	(0.34, 0.90)		100.0
		0.01	0.10 1.00 10.00 100	0.00			
Heterogeneity: $l^2 = 43\%$ , $\tau^2 = 0.08$			0.17 df = 1 (n = 0.69)				

Test for subgroup differences (common effect):  $\chi_1^2 = 0.17$ , df = 1 (p = 0.68) Test for subgroup differences (random effect):  $\chi_1^2 = 0.18$ , df = 1 (p = 0.68)

Both fixed-effect and random-effect models were used. Notes: The light gray spots indicate the estimated odds ratio for each study, with the extending lines indicating the estimated 95% CI; the blue square indicates the weights of each study; and the light gray and maroon rhombuses indicate the estimated odds ratio (95% CI) calculated using the fixed-effect model and random-effect model, respectively, for all patients included in each subgroup. EVD = external ventricular drainage; TE = treatment estimate; seTE = standard error of treatment estimate; RCT = randomized control trial.

emergency operation (OR = 2.63, 95% CI 0.47–14.59, p = 0.269), prophylactic antibiotics (OR = 0.87, 95% CI 0.66–1.14, p = 0.308), artificial ventilation (OR = 1.58, 95% CI 0.65–3.84, p = 0.308), and single room (OR = 1.95, 95% CI 0.76–4.97, p = 0.163) (Figures 2 and 3).

The results of "leave-one-out" sensitivity analysis are presented in eFigures 4–32 (links.lww.com/CPJ/A438).

## **Subgroup Analysis**

Finally, we performed a subgroup analysis on the effect of antibiotic-impregnated catheters on the reduction of EVD-related infection rates. Subgroup analysis was performed according to study type. The fixed-effect and random-effect models were applied according to heterogeneity. As shown in Figure 4, we found that the use of antibiotic-impregnated catheters could reduce EVD-related infections, but without statistical significance in RCTs (OR = 0.37, 95% CI 0.07–2.06, p = 0.257). However, observational studies (OR = 0.55, 95% CI 0.30–0.99, p = 0.047) and consolidated results (OR = 0.60, 95% CI 0.41–0.88, p = 0.009) support the use of antibiotic-impregnated catheters.

## **Study Bias Assessment**

The study-wise odds ratio estimates were plotted against their corresponding standard errors (eFigures 33–61, links. lww.com/CPJ/A438). Funnel plot analysis for studies of sex (male) revealed that 2 of 30 studies fell out of the 95% confidence bounds, but there was no funnel plot asymmetry (that is, no systematic relationship between risk ratios and associated study precision). Funnel plot analysis for SAH/ IVH (3 of 21 studies), brain trauma (2 of 15 studies), other neurosurgical procedures (1 of 7 studies), bilateral EVDs (1 of 5 studies), insertion of catheters outside the OR (4 of 10 studies), insertion during craniotomy (1 of 3 studies), CSF leak (1 of 8 studies), and prophylactic antibiotics (2 of 14 studies) showed similar results. Funnel plot asymmetry has been found in studies on diabetes mellitus. However, we detected no indication of publication bias using the Duval trim-and-fill method (no new studies added).<sup>e7</sup>

# Discussion

Previously, a few meta-analyses have identified risk factors for the development of EVD-related infections. The metaanalysis of various relevant factors in the onset of EVDrelated infection in patients who underwent EVD enabled us to establish a more probable profile for patients who are more likely to develop it during treatment. Overall, 7 potential risk factors (SAH/IVH, concomitant systemic infection, other neurosurgical procedures, change of catheter, bilateral EVDs, CSF leak, and duration of EVD >7 days) and 2 protective factors (use of silver-coated and antibiotic-impregnated catheters) were identified. With the change in diagnosis criteria and the stringent placement and maintenance protocols applied, the overall EVD-related infection rate was 2.2%–36.2% in the included studies.

We found that SAH and IVH were associated with a high risk of EVD-related infections. One possible explanation being that intraventricular blood could form a culture medium for bacterial growth. Moreover, the inflammatory response and impaired systemic immunity may contribute to the high

infection rate. In a study by Sweid et al., 45% of patients were diagnosed with subarachnoid hemorrhage and intracerebral hemorrhage, and these patients were often bedridden and immunocompromised.<sup>60</sup> In addition, patients with blood in the CSF had a longer duration of EVD and more manipulations of the drainage system, such as CSF sampling. Infected patients may have other potential risk factors, and further studies are needed to confirm this. By contrast, intracranial hemorrhage, another important indication for EVD, was not associated with a higher rate of EVD-related infections in our study (OR = 0.86, 95% CI 0.66-1.12, p = 0.249). This could be attributed to the initial heterogeneous alteration in CSF parameters after ICH or SAH because CSF values might show abnormal results even in the absence of an EVD-associated infection.<sup>e2</sup> However, ICH may extend into intraventricular areas, denoted as IVH; it happens in 40%-60% of patients with ICH and is associated with complications and poor outcomes.<sup>e8-e10</sup> Therefore, there was also a possibility that the different results between EVD/IVH and ICH were due to the fact that some studies might categorize patients with ICH with SAH/IVH extension as having SAH/IVH. However, detailed classification criteria were not provided for most of the included studies. Thus, more attention should be paid to patients with ICH who have a potential risk of hemorrhage expansion.

Several studies have found a trend toward the development of EVD-related infections in patients with concomitant systemic infections, but the relationship was not statistically significant.<sup>31,45,e2</sup> However, we demonstrated in our metaanalysis that patients with concomitant systemic infection had almost double the risk of EVD-related infection (OR = 1.90, 95% CI 1.34–2.70, p < 0.001). Microorganisms found in the CSF were also found in samples from other parts of the body in 17% of cases in the study by Thompson et al.<sup>52</sup> and in 50% of cases in the study by Kim et al.<sup>31</sup> This might be explained by hematogenous seeding. This finding emphasizes the need to investigate and treat systemic infections. The increasing use of prophylactic antibiotics might also contribute to the concordance rates of microorganisms found in CSF and systemic cultures. Interestingly, diabetes (OR = 1.25, 95% CI 0.90 - 1.75, p = 0.178) and steroid use (OR = 1.52, 95% CI 0.96-2.41, p = 0.074) were not significant risk factors. This suggests that EVD-related infections do not share the same patient-related risk factors as other infections, such as surgical site infections. Steroids are recommended for patients with tumor-related cerebral edema. However, an updated meta-analysis conducted by Wintzer et al. indicated a lack of clear evidence of the beneficial or adverse effects of steroids.<sup>e11</sup> This finding is consistent with the results of our study.

EVD insertion with other neurosurgical procedures was associated with a high risk of infection (OR = 1.76, 95% CI 1.02-3.04, p = 0.041). However, significant heterogeneity was observed among the included studies. Both studies reporting significant relationships defined the specific period

of neurosurgical procedures recorded (Kirmani et al. recorded other neurosurgical procedures performed within 2 weeks of EVD insertion or any time in the duration of ventriculostomy, and Kim et al. recorded all craniotomy operations performed in patients with a catheter).<sup>42,e3</sup> This phenomenon was also reported by Holloway et al. and Mayhall et al.<sup>e12,e13</sup>. We considered that this was due to immunosuppression accompanying the trauma and the operative procedure. However, the "leave-one-out" sensitivity analysis we conducted showed that the overall OR was 1.29  $(95\% \text{ CI } 0.95-1.76, \text{ I}^2 = 24\%)$  when excluding the study by Kirmani et al. from the meta-analysis of studies reporting the relationship between EVD-related infection and other neurosurgical procedures (eFigure 16, links.lww.com/CPJ/ A438). Considering that EVD is often performed in neurosurgery, it is hoped that more related studies can be conducted in the future.

Considering that EVD-related infection is closely associated with colonization and biofilm formation on catheters, catheters with antibacterial effects were introduced to reduce the infection rate. The first study on antibiotic-impregnated catheters was conducted by Gower et al., and a reduction of 54% of Staphylococcus epidermidis adherence to the catheter surface was found with catheters soaked in Bacitracin A for half an hour.<sup>e14</sup> The Bactiseal<sup>®</sup> EVD Catheter system (Codman, Raynham, MA) impregnated with 0.15% clindamycin and 0.054% rifampicin was used more often. It allows for the release of antibiotics into the lumen of the EVD for up to 50 days after insertion.<sup>e15</sup> The EVD-related infection rate was significantly reduced (OR = 0.60, 95% CI 0.41–0.88, p = 0.009) with the application of antibioticimpregnated catheters in our meta-analysis. However, the effect is not reliable under sensitivity analysis, and it might be caused by the different definitions of infection. Silver is another choice for EVD catheters because of its broad antimicrobial spectrum.<sup>e16</sup> In our meta-analysis, the use of silver-coated catheters significantly reduced the rate of EVD-related infections (OR = 0.57, 95% CI 0.38-0.87, p = 0.008). Similar results were obtained in a network meta-analysis conducted by Goda et al.<sup>e17</sup> Large amounts of Ag have been reported to result in organ accumulation and toxicity.<sup>e18</sup> However, no toxic effects were observed in the studies included in our meta-analysis. We found that silver-coated catheters seemed to have a more convincing effect on the reduction in EVD-related infection rates. However, antibiotic-impregnated catheters demonstrated a statistically significant lower rate of infection than silver-coated catheters (RR = 0.47, 95% CI 0.25-0.87) in a network meta-analysis including 7 trials.<sup>e17</sup> Apart from the antibacterial and adverse effects of different catheters, cost implications should also be taken into consideration.

A change in catheter is usually required for infection, blockage, or inadvertent dislodgment. A higher infection rate associated with catheter replacement was observed in our meta-analysis (OR = 5.05, 95% CI 3.67–6.96, p < 0.001). A previous study demonstrated that previous ventriculostomy did not increase the risk of infection with subsequent procedures.<sup>e13</sup> Mayhall et al. believed that prophylactic

Copyright © 2023 American Academy of Neurology. Unauthorized reproduction of this article is prohibited.

replacement of catheters every 5 days could reduce EVDrelated infections by reducing the duration of EVDs. Based on the results obtained in our meta-analysis, we suggest that catheters should not be changed, unless necessary. In addition, avoiding dislodging of EVDs might be an effective procedure to reduce the infection rate, owing to the high risk of EVDs replacement. Using image guidance, meticulous securing of the catheters and reinforcement with medical and nursing staff might help achieve this target. Bilateral EVD was another significant risk factor in our meta-analysis (OR = 2.25, 95% CI 1.03–4.89, *p* = 0.041). Bilateral EVDs can accelerate blood drainage, which can shorten the duration of drainage. This might be beneficial in severe IVH because of the more pronounced IVH reduction in patients treated with bilateral EVDs. However, it is clear that the placement of additional catheters could lead to a higher risk of infection. In addition, patients with bilateral EVDs usually have more severe conditions, which could increase the infection rate. Therefore, enhanced surveillance and control of infection are required when neurosurgeons use bilateral EVD. More studies are required to demonstrate the relationship between bilateral EVDs and EVD-related infections. In our study, insertion of catheters in the emergency department/ intensive care unit was not associated with a higher rate of EVD-related infection (OR = 1.11, 95% CI 0.60–2.07, p =0.736) compared with the operating room. This is beyond our expectations because placement in the operating room provides the advantages of a sterile environment, irrigation, and suction. We believe that the increasing use of standardized techniques may be an explanation. Optimized antiseptic and insertion techniques are of great importance considering that placement outside the operating room is necessary for urgent indications.

CSF leakage is considered a major risk factor for EVD-related infection.<sup>50</sup> We also find CSF leak to be a significant contributor (OR = 3.19, 95% CI 2.12-4.81, p < 0.001). Poor wound healing, high intracranial pressure, and surgical factors may contribute to leakage. Extraluminal progression of pathogens initially colonizing the skin site where CSF leaks might cause EVD-related infection. The relationship between the duration of EVD >7 days and higher infection rate was confirmed in most studies, although the cause-andeffect relationship has not been determined.<sup>16,29,30,45,49,e3,e4</sup> The possibility of infection drastically increased when the catheters were inserted for 7 days or more (OR = 4.62, 95% CI 2.26–9.43, *p* < 0.001). Stroknik et al. mentioned similar results.<sup>35</sup> Bacteria might be difficult to eradicate without catheter removal because they can form a biofilm along the lumen of the catheter. Therefore, we recommend careful consideration of whether to insert the catheters for >7 days, depending on the patient's condition. The 2017 IDSA guidelines for Healthcare-Associated Ventriculitis and Meningitis recommended periprocedural prophylactic antimicrobial administration for patients undergoing placement of EVD.<sup>e19</sup> However, our meta-analysis showed that the use of prophylactic antibiotics did not significantly decrease the rate of EVD-related infections (OR = 0.87, 95% CI 0.66–1.14, p = 0.309). Furthermore, indiscriminate use may cause infections with resistant germs, anaphylactic reactions, prolonged bleeding times, and systemic toxicity. The selection of resistant microbial species could occur even at subminimum inhibitory concentration levels.<sup>e20</sup> Considering these aspects, we recommend not using prophylactic antibiotics. Therefore, it would be more effective to use antibiotic-impregnated catheters to prevent EVD-related infections.

As mentioned in a statement from the Neurocritical Care Society,<sup>2</sup> care bundles including attention to sterile techniques, tunneling of the catheter, periprocedural antibiotic use only, use of an impregnated catheter, use of a closed system, no routine CSF sampling, use of a sterile dressing, and no site changes after placement are recommended for reduction in EVD-related infection rates.<sup>7,e21,e22</sup> However, most of the approaches used individually did not significantly change the infection rates in our meta-analysis, which is consistent with this statement. Owing to the different elements of care bundles, it is not certain which parts were effective in reducing EVD-related infection rates. We also analyzed other factors, such as hypertension, insertion during surgery, and artificial ventilation. However, none of the differences were statistically significant.

Statistically significant heterogeneity was found in some analyses, most of which were caused by differences in study design, especially in the definition of risk factors. Other studies reported factors such as skull fracture,<sup>20</sup> smoking,<sup>52</sup> and flushing catheters.<sup>60</sup> However, the number of studies investigating these factors was small, and the studies were largely heterogeneous. Therefore, it was impossible to conduct a meta-analysis. We hope that more studies with unified diagnostic criteria and a prospective design could be conducted to help identify the risk factors for EVD-related infection.

One of the limitations of our study was that most of the included studies had cohort designs and most were retrospective studies. In addition, there were 2 CDC criteria for the diagnosis of meningitis/ventriculitis (eTable 3, links.lww. com/CPJ/A438). The exclusive use of criterion one might lead to artificially low infection rates. The adoption of different diagnostic criteria might cause unavoidable heterogeneity, especially when studies mention new techniques.

External ventricular drainage is a vital tool in neurosurgery and carries a non-negligible risk of EVD-related infections. We demonstrated some potential risk factors, including SAH/IVH, concomitant systemic infection, other neurosurgical procedures, change of catheter, bilateral EVDs, CSF leak, and duration of EVD > 7 days in our meta-analysis. The use of silver-coated and antibiotic-impregnated catheters may help reduce the risk of infection. However, some controversial factors such as diabetes mellitus, steroid use, and prophylactic antibiotics were not associated with an increased or decreased risk of an EVD-related infection. More studies with unified diagnostic criteria and a prospective design are warranted to clarify the cause-and-effect relationship.

Neurology.org/CP

# **Study Funding**

The authors report no targeted funding.

## Disclosure

All authors report no disclosures relevant to the manuscript. Full disclosure form information provided by the authors is available with the full text of this article at Neurology.org/cp.

# **Publication History**

Received by *Neurology: Clinical Practice* June 6, 2022. Accepted in final form February 21, 2023. Submitted and externally peer reviewed. The handling editor was Deputy Editor Kathryn Kvam, MD.

#### Appendix Authors

Name	Location	Contribution
Jialei Zhou, MM	Department of Neurosurgery & Brain and Nerve Research Laboratory, The First Affiliated Hospital of Soochow University Suzhou, Jiangsu Province, China	Drafting/revision of the manuscript for content, including medical writing for content; major role in the acquisition of data; study concept or design; analysis or interpretation of data
Yi Zhong, MM	Department of Neurosurgery & Brain and Nerve Research Laboratory, The First Affiliated Hospital of Soochow University Suzhou, Jiangsu Province, China	Drafting/revision of the manuscript for content, including medical writing for content; major role in the acquisition of data; study concept or design
Xiang Li, MD	Department of Neurosurgery & Brain and Nerve Research Laboratory, The First Affiliated Hospital of Soochow University Suzhou, Jiangsu Province, China	Drafting/revision of the manuscript for content, including medical writing for content; study concept or design; analysis or interpretation of data
Hang Li, MM	Department of Neurosurgery & Brain and Nerve Research Laboratory, The First Affiliated Hospital of Soochow University Suzhou, Jiangsu Province, China	Drafting/revision of the manuscript for content, including medical writing for content; study concept or design
Jiahe Wang, MM	Department of Neurosurgery & Brain and Nerve Research Laboratory, The First Affiliated Hospital of Soochow University Suzhou, Jiangsu Province, China	Drafting/revision of the manuscript for content, including medical writing for content; study concept or design
Siyuan Yang, MM	Department of Neurosurgery & Brain and Nerve Research Laboratory, The First Affiliated Hospital of Soochow University Suzhou, Jiangsu Province, China	Drafting/revision of the manuscript for content, including medical writing for content; analysis or interpretation of data
Gang Chen, MD, PhD	Department of Neurosurgery and Brain & Nerve Research Laboratory, The First Affiliated Hospital of Soochow University Suzhou, Jiangsu Province, China	Drafting/revision of the manuscript for content, including medical writing for content; major role in the acquisition of data; study concept or design; analysis or interpretation of data

#### References

- Dorresteijn KRIS, Jellema K, van de Beek D, Brouwer MC. Factors and measures predicting external CSF drain-associated ventriculitis: a review and meta-analysis. *Neurology*. 2019;93(22):964-972.
- Fried HI, Nathan BR, Rowe AS, et al. The insertion and management of external ventricular drains: an evidence-based consensus statement: a statement for healthcare professionals from the Neurocritical Care Society. *Neurocrit Care*. 2016; 24(1):61-81.
- Dossani RH, Patra DP, Terrell DL, Willis B. Placement of an external ventricular drain. N Engl J Med. 2021;384(2):e3.
- Brain Trauma Foundation, American Association of Neurological Surgeons, Congress of Neurological Surgeons, et al. Guidelines for the management of severe traumatic brain injury. VII. Intracranial pressure monitoring technology. J Neurotrauma. 2007; 24(suppl 1):S45-S54.
- Maniker AH, Vaynman AY, Karimi RJ, Sabit AO, Holland B. Hemorrhagic complications of external ventricular drainage. *Neurosurgery*. 2006;59(suppl\_4):ONS419-ONS-424; discussion ONS424-425.
- Arabi Y, Memish ZA, Balkhy HH, et al. Ventriculostomy-associated infections: incidence and risk factors. Am J Infect Control. 2005;33(3):137-143.
- Korinek A-M, Reina M, Boch AL, Rivera AO, De Bels D, Puybasset L. Prevention of external ventricular drain-related ventriculitis. *Acta Neurochir (Wien)*. 2005;147(1): 39-45; discussion 45-46.
- Sussman ES, Kellner CP, Nelson E, et al. Hemorrhagic complications of ventriculostomy: incidence and predictors in patients with intracerebral hemorrhage. *J Neurosurg.* 2014;120(4):931-936.
- O'Neill BR, Velez DA, Braxton EE, Whiting D, Oh MY. A survey of ventriculostomy and intracranial pressure monitor placement practices. *Surg Neurol.* 2008;70(3): 268-273; discussion 273.
- Rehman T, Rehman A, Rehman A, et al. A US-based survey on ventriculostomy practices. Clin Neurol Neurosurg. 2012;114(6):651-654.
- Kakarla UK, Kim LJ, Chang SW, Theodore N, Spetzler RF. Safety and accuracy of bedside external ventricular drain placement. *Neurosurgery*. 2008;63(1): ONS162-ONS166; discussion ONS166-167.
- Tanweer O, Boah A, Huang PP. Risks for hemorrhagic complications after placement of external ventricular drains with early chemical prophylaxis against venous thromboembolisms. J Neurosurg. 2013;119(5):1309-1313.
- Humphreys H, Jenks PJ. Surveillance and management of ventriculitis following neurosurgery. J Hosp Infect. 2015;89(4):281-286.
- Peter S, Roman B. External ventricular drainage infections: a single-centre experience on 100 cases. J Neurol Neurophysiol. 2016;7. Accessed March 14, 2022. omicsonline. org/open-access/external-ventricular-drainage-infections-a-singlecentre-experienceon100-cases-2155-9562-1000392.php?aid=78976.
- Hussain S, Raza A, Shahid S, Asif H, Ahmad U, Ashraf N. Postoperative reduction of intraventricular hemorrhage volume: single- versus dual-catheter drainage. J Neurol Surg A Cent Eur Neurosurg. 2018;79(4):279-284.
- Hoefnagel D, Dammers R, Ter Laak-Poort MP, Avezaat CJJ. Risk factors for infections related to external ventricular drainage. *Acta Neurochir (Wien)*. 2008;150(3): 209-214; discussion 214.
- Zeng X, Zhang Y, Kwong JSW, et al. The methodological quality assessment tools for preclinical and clinical studies, systematic review and meta-analysis, and clinical practice guideline: a systematic review. J Evid Based Med. 2015;8(1):2-10.
- Cumpston M, Li T, Page MJ, et al. Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions. *Cochrane Database Syst Rev.* 2019;10:ED000142.
- Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in metaanalyses. BMJ. 2003;327(7414):557-560.
- Stenager E, Gerner-Smidt P, Kock-Jensen C. Ventriculostomy-related infections: an epidemiological study. Acta Neurochir (Wien). 1986;83(1-2):20-23.
- Bogdahn U, Lau W, Hassel W, Gunreben G, Mertens HG, Brawanski A. Continuous-pressure controlled, external ventricular drainage for treatment of acute hydrocephalus-evaluation of risk factors. *Neurosurgery*. 1992;31(5):898-903; discussion 903-904.
- Alleyne CHJ, Hassan M, Zabramski JM. The efficacy and cost of prophylactic and perioprocedural antibiotics in patients with external ventricular drains. *Neurosurgery*. 2000;47(5):1124-1127; discussion 1127-1129.
- Zabramski JM, Whiting D, Darouiche RO, et al. Efficacy of antimicrobial-impregnated external ventricular drain catheters: a prospective, randomized, controlled trial. J Neurosurg. 2003;98(4):725-730.
- 24. Fichtner J, Güresir E, Seifert V, Raabe A. Efficacy of silver-bearing external ventricular drainage catheters: a retrospective analysis. J Neurosurg. 2010;112(4):840-846.
- Gutiérrez-González R, Boto GR, Fernández-Pérez C, del Prado N. Protective effect of rifampicin and clindamycin impregnated devices against *Staphylococcus* spp. infection after cerebrospinal fluid diversion procedures. *BMC Neurol.* 2010;10(1):93.
- Muttaiyah S, Ritchie S, John S, Mee E, Roberts S. Efficacy of antibiotic-impregnated external ventricular drain catheters. J Clin Neurosci. 2010;17(3):296-298.
- Omar MA, Mohd Haspani MS. The risk factors of external ventricular drainagerelated infection at hospital kuala lumpur: an observational study. *Malays J Med Sci.* 2010;17(3):48-54.
- Scheithauer S, Bürgel U, Bickenbach J, et al. External ventricular and lumbar drainageassociated meningoventriculitis: prospective analysis of time-dependent infection rates and risk factor analysis. *Infection*. 2010;38(3):205-209.
- Camacho EF, Boszczowski I, Basso M, et al. Infection rate and risk factors associated with infections related to external ventricular drain. *Infection*. 2011;39(1):47-51.
- Williams TA, Leslie GD, Dobb GJ, Roberts B, van Heerden PV. Decrease in proven ventriculitis by reducing the frequency of cerebrospinal fluid sampling from extraventricular drains. J Neurosurg. 2011;115(5):1040-1046.
- 31. Kim J-H, Desai NS, Ricci J, et al. Factors contributing to ventriculostomy infection. *World Neurosurg.* 2012;77(1):135-140.

- Lemcke J, Depner F, Meier U. The impact of silver nanoparticle-coated and antibioticimpregnated external ventricular drainage catheters on the risk of infections: a clinical comparison of 95 patients. Acta Neurochir Suppl. 2012;114:347-350.
- Pople I, Poon W, Assaker R, et al. Comparison of infection rate with the use of antibiotic-impregnated vs standard extraventricular drainage devices: a prospective, randomized controlled trial. *Neurosurgery*. 2012;71(1):6-13.
- Lajcak M, Heidecke V, Haude KH, Rainov NG. Infection rates of external ventricular drains are reduced by the use of silver-impregnated catheters. *Acta Neurochir (Wien)*. 2013;155(5):875-881.
- Strojnik T, Golc J, Zakelšek J. Infections of external ventricular drainages. Cent Eur J Med. 2013;8(2):250-256.
- 36. Wright K, Young P, Brickman C, et al. Rates and determinants of ventriculostomyrelated infections during a hospital transition to use of antibiotic-coated external ventricular drains. *Neurosurg Focus.* 2013;34(5):E12.
- 37. Chatzi M, Karvouniaris M, Makris D, et al. Bundle of measures for external cerebral ventricular drainage-associated ventriculitis. *Crit Care Med.* 2014;42(1):66-73.
- Chen C, Zhang B, Yu S, et al. The incidence and risk factors of meningitis after major craniotomy in China: a retrospective cohort study. *PLoS One*. 2014;9(7):e101961.
- Hagel S, Bruns T, Pletz MW, Engel C, Kalff R, Ewald C. External ventricular drain infections: risk factors and outcome. *Interdiscip Perspect Infect Dis*. 2014;2014:708531.
- Mikhaylov Y, Wilson TJ, Rajajee V, et al. Efficacy of antibiotic-impregnated external ventricular drains in reducing ventriculostomy-associated infections. J Clin Neurosci. 2014;21(5):765-768.
- Foreman PM, Hendrix P, Griessenauer CJ, Schmalz PGR, Harrigan MR. External ventricular drain placement in the intensive care unit versus operating room: evaluation of complications and accuracy. *Clin Neurol Neurosurg.* 2015;128:94-100.
- Kirmani AR, Sarmast AH, Bhat AR. Role of external ventricular drainage in the management of intraventricular hemorrhage; its complications and management. Surg Neurol Int. 2015;6(1):188.
- Atkinson R, Fikrey L, Jones A, Pringle C, Patel HC. Cerebrospinal fluid infection associated with silver-impregnated external ventricular drain catheters. *World Neurosurg*, 2016;89:505-509.
- Shekhar H, Kalsi P, Dambatta S, Strachan R. Do antibiotic-impregnated external ventriculostomy catheters have a low infection rate in clinical practice? A retrospective cohort study. *Br J Neurosurg*. 2016;30(1):64-69.
- Dos Santos SC, Fortes Lima TT, Lunardi LW, Stefani MA. External ventricular drain-related infection in spontaneous intracerebral hemorrhage. World Neurosurg. 2017;99:580-583.
- Fu RZ, Anwar DR, Laban JT, Maratos EC, Minhas PS, Martin AJ. Pre-emptive intrathecal vancomycin therapy reduces external ventricular drain infection: a single centre retrospective case-control study. *Br J Neurosurg*. 2017;31(1):16-20.
- Woo PYM, Wong H-T, Pu JKS, et al. Moving the goalposts: a comparison of different definitions for primary external ventricular drain infection and its risk factors: a multicenter study of 2575 patients. J Clin Neurosci. 2017;45:67-72.
- 48. Kohli G, Singh R, Herschman Y, Mammis A. Infection incidence associated with external ventriculostomy placement: a comparison of outcomes in the emergency

department, intensive care unit, and operating room. *World Neurosurg.* 2018;110: e135-e140.

- Nilsson A, Uvelius E, Cederberg D, Kronvall E. Silver-coated ventriculostomy catheters do not reduce rates of clinically diagnosed ventriculitis. *World Neurosurg.* 2018; 117:e411-e416.
- Park J, Choi Y-J, Ohk B, Chang H-H. Cerebrospinal fluid leak at percutaneous exit of ventricular catheter as a crucial risk factor for external ventricular drainage-related infection in adult neurosurgical patients. *World Neurosurg.* 2018;109:e398-e403.
- Shang F, Wang K, Xu Y, Wang N, Chen W, Cheng W. Assessment of risk factors for external ventricular drainage-induced infections in the neurosurgery department. *Int J Clin Exp Med.* 2018;11:12664-12669.
- Thompson DR, Vlachos S, Patel S, Innocent S, Tolias C, Barkas K. Recurrent sampling and ventriculostomy-associated infections: a case-control study. *Acta Neurochir* (*Wien*). 2018;160(5):1089-1096.
- Zheng F, Xu H, von Spreckelsen N, et al. Early or late cranioplasty following decompressive craniotomy for traumatic brain injury: a systematic review and metaanalysis. J Int Med Res. 2018;46(7):2503-2512.
- Berger-Estilita J, Passer M, Giles M, Wiegand J, Merz TM. Modalities and accuracy of diagnosis of external ventricular drainage-related infections: a prospective multicentre observational cohort study. *Acta Neurochir (Wien)*. 2018; 160(10):2039-2047.
- Hoffman H, Jalal MS, Chin LS. The incidence of meningitis in patients with traumatic brain injury undergoing external ventricular drain placement: a nationwide inpatient sample analysis. *Neurocrit Care*. 2019;30(3):666-674.
- Hussein K, Rabino G, Feder O, et al. Risk factors for meningitis in neurosurgical patients with cerebrospinal fluid drains: prospective observational cohort study. Acta Neurochir (Wien). 2019;161(3):517-524.
- Katzir M, Lefkowitz JJ, Ben-Reuven D, Fuchs SJ, Hussein K, Sviri GE. Decreasing external ventricular drain-related infection rates with duration-independent, clinically indicated criteria for drain revision: a retrospective study. *World Neurosurg*. 2019;131: e474-e481.
- Altschul D, Hamad MK, Kobets A, et al. A retrospective quality analysis of external ventricular drain infection rates following stroke diagnoses and other brain injuries: comparison of emergency room and ICU/OR setting. *Cureus*. 2020;12(3):e7173.
- Larsen IC, Matias JEF, Moro MS, Maranha LA, Araújo JC. Infecção liquórica em drenagem ventricular externa: avaliação dos fatores de risco em 110 pacientes de uma única instituição. Arq Bras Neurocir. 2020;39(3):161-169.
- Sweid A, Weinberg JH, Abbas R, et al. Predictors of ventriculostomy infection in a large single-center cohort. J Neurosurg. 2020;134(4):1218-1225.

eReferences are listed at links.lww.com/CPJ/A438.

How to cite this article: Zhou J, Zhong Y, Li X, et al. Risk factors for external ventricular drainage-related infection: A systematic review and meta-analysis. *Neurol Clin Pract.* 2023;13(4):e200156. doi: 10.1212/CPJ.000000000200156.